🇮🇳IN
Sign In
GL

GLAXO

NSE

GlaxoSmithKline Pharmaceuticals Limited

₹2,515.10

+17.10(+0.68%)

Group Companies

Foreign Flows

sector level — not this stock
Healthcare sector+₹2,114 Crnet foreign buying
2026-09-01 to 2026-09-15

This is the flow into the whole Healthcare sector, not into GLAXO. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.

Supply Chain

suppliers and customers in the graph

Relationship Network

directors, institutions, group entities

Macro Sensitivity

rates, currency, commodities

Revenue by Segment

Business Group

Geographic Exposure

revenue, imports, currency

Scenario analysis

stated assumptions, shown workings

GLAXO exposure summary

GlaxoSmithKline Pharmaceuticals Limited reports a single business segment, Pharmaceuticals. GlaxoSmithKline Pharmaceuticals Limited is a constituent of 5 indices, with its largest weights in S&P BSE 200 (0.06%), S&P BSE 500 (0.06%), NIFTY 500 (0.05%). 16 exchange-traded funds hold the stock.

Index memberships5
ETFs holding16

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer